Article Text

Download PDFPDF
Hormone therapy increased incidence and severity of urinary incontinence in healthy postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In healthy postmenopausal women, what is the effect of hormone therapy (HT) on urinary incontinence (UI)?

Clinical impact ratings GP/FP/Primary care ★★★★★★★ Gynaecology ★★★★★★☆


Embedded ImageDesign:

randomised, placebo controlled trial (Women’s Health Initiative [WHI]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}.*

Embedded ImageFollow up period:

1 year.

Embedded ImageSetting:

40 US clinical centres.

Embedded ImageParticipants:

women who were 50–79 years of age and postmenopausal. Exclusion criteria: breast cancer, other invasive cancer in past 10 years, venous thromboembolism, hypertriglyceridaemia, or condition with poor prognosis. 16 608 women {mean age 63.3 y} were in the oestrogen plus progestin trial, and 10 739 women (mean age 64 …

View Full Text


  • * See glossary.

  • For correspondence: Dr S Hendrix, Wayne State University School of Medicine/Hutzel Women’s Hospital, Detroit, MI, USA.

  • Source of funding: National Heart, Lung and Blood Institute.